Warby Parker/$WRBY
1D1W1MYTD1Y5YMAX
Capital at risk
About Warby Parker
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
- Ticker
- $WRBY
- Sector
- Consumer Discretionary
- Primary listing
- NYSE
- Employees
- 3,156
- Headquarters
- New York, United States
- Website
- www.warbyparker.com
Warby Parker Metrics
BasicAdvanced
$3B
401.41
$0.06
1.93
-
Price and volume
Market cap
$3B
Beta
1.93
52-week high
$31.00
52-week low
$14.96
Average daily volume
2.6M
Financial strength
Current ratio
2.268
Quick ratio
1.803
Long term debt to equity
0.55
Total debt to equity
0.64
Profitability
EBITDA (TTM)
41.468
Gross margin (TTM)
53.12%
Net profit margin (TTM)
0.85%
Operating margin (TTM)
-1.32%
Effective tax rate (TTM)
21.85%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-1.16%
Return on equity (TTM)
2.06%
Valuation
Price to earnings (TTM)
401.408
Price to revenue (TTM)
3.273
Price to book
7.61
Price to tangible book (TTM)
7.61
Price to free cash flow (TTM)
137.196
Free cash flow yield (TTM)
0.73%
Free cash flow per share (TTM)
0.176
Growth
Revenue change (TTM)
10.99%
Earnings per share change (TTM)
-176.06%
3-year revenue growth (CAGR)
12.91%
3-year earnings per share growth (CAGR)
-53.80%
What the Analysts think about Warby Parker
Analyst ratings (Buy, Hold, Sell) for Warby Parker stock.
Analyst projections of the future price of Warby Parker stock.
Bulls say / Bears say
Q2 revenue rose 9.8% to $235.5m, while active customers grew 4.1% and average revenue per customer rose 6.6%. Retail revenue grew 13.6%, showing that the omnichannel model is still expanding. (Morningstar)
Eye exams grew by more than 30% year on year and reached about 7% of revenue, with exams available in roughly 90% of stores. Warby Parker believes this could eventually reach 15–20%, giving its retail network a larger healthcare role. (The Motley Fool)
The planned Intelligent Eyewear launch with Google and Samsung is a meaningful upside option that is not included in 2026 revenue guidance. Warby Parker is preparing its 352 stores to demonstrate the product, so successful adoption could add growth beyond the existing 10–12% outlook. (Vision Monday, Morningstar)
Customer acquisition remains a weak spot: active customers grew only 4.1%, and management cited traffic headwinds. It is taking a prudent stance on third-quarter growth while investing to improve customer numbers. (The Motley Fool)
Q2’s 57.9% gross margin and 14% adjusted EBITDA margin were helped by an $11.8m tariff refund. Doctor and occupancy costs also grew faster than revenue as stores opened, so the reported margin improvement may not be repeatable. (Morningstar, Vision Monday)
Intelligent Eyewear is still unproven: 2026 guidance includes launch costs but no revenue or halo benefit. A weak launch would leave Warby Parker carrying extra marketing and technology spending without the hoped-for new growth engine. (Morningstar, Vision Monday)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
Warby Parker Financial Performance
Revenues and expenses
Warby Parker Earnings Performance
Company profitability
Upcoming events
No upcoming events
Warby Parker News
AllArticlesVideos
Funds containing Warby Parker
AllUSDGBPEUR
Fund name | Fund size | $WRBY weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.14% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.14% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.08% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.04% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.